New York, October 1 (FinanceEnquiry.com) – Analysts at Bank of America Merrill Lynch reiterate their NEUTRAL rating on the shares of Boston Scientific Corporation (NYSE: BSX). The 12-month price objective has been reduced from $8.50 to $6.30.
In a research note published on September 28, the analysts mention that more confidence is needed on the topic that Boston Scientific can develop. Furthermore, so to permit for operating leverage, more assurance is needed that falls of ASP in the core drug-eluting stent market of the company will moderate and the Promus Element stent can be unbeaten in the US for being more bullish on Boston Scientific Corporation.
In addition to this, despite the fact that plan of BSX’s management to play out is waited, it would be very easier to call Boston Scientific Corporation inexpensive and to fight that an optimistic risk or reward exists if convincing attitude is carried on the subject of operating leverage that it will be materialized. Moreover, on September 27, Boston Scientific Corporation was closed at $5.66, the analysts add further.
In a...Stocks Mount on Chairman Ben’s remarks - February 28, 2013
New York, February 28 (FinanceEnquiry.com) – Seeing that Federal Reserve Chairman Ben Bernanke stayed unwavering in supporting the stimulus policy of Fed and data signaled to economic development, stocks...Deutsche Bank Securities Reiterates BUY Rating on American International Group (NYSE: AIG), Target Price Raised - February 27, 2013
New York, February 27 (FinanceEnquiry.com) – Analyst Joshua Shanker at Deutsche Bank Securities reiterates BUY rating on the shares of American International Group, Inc (NYSE: AIG). The 12-month target price has...Deutsche Bank Securities Reiterates BUY Rating on Portland General Electric Company (NYSE: POR) - February 26, 2013
In a...Deutsche Bank Securities Reiterates BUY Rating on TripAdvisor (NASDAQ: TRIP) - December 25, 2012
New York, December 24 (FinanceEnquiry.com) – Analysts at JP Morgan reiterate their OVERWEIGHT rating on the shares of The Carlyle Group (NASDAQ: CG). The 12-month target price has been raised to some...Taglich Brothers Reiterates SPECULATIVE BUY Rating on Sonic Foundry (NASDAQ: SOFO), Target Price Reduced - December 24, 2012
New York, December 24 (FinanceEnquiry.com) – Analysts at Taglich Brothers reiterate their SPECULATIVE BUY rating on the shares of Sonic Foundry (NASDAQ: SOFO). The 12-month target price has been reduced...Deutsche Bank Securities Reports on Retailing/Hardlines – Hardline Headlines - December 20, 2012
In a research note published on December 17, the analysts mention that...